[Interleukin-2 and cancer immunotherapy].
Ogarkov
V I
VI
Dobkin
A I
AI
Ryzhova
E V
EV
Okulov
V B
VB
Kiselev
O I
OI
D000818:Animals; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007116:Immunization, Passive; D007153:Immunologic Deficiency Syndromes / Q000276:immunology / Q000628:therapy; D007167:Immunotherapy / Q000379:methods*; D007376:Interleukin-2 / Q000009:adverse effects / Q000627:therapeutic use*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use
D007376:Interleukin-2; D011994:Recombinant Proteins
Interleĭkin-2 i immunoterapiia raka.